Pharsight

1. List of Vascepa drug patents

Application	Filing Date	Opposition Party	Legal Status
EP17187534A	2021-12-10	Cooke, Richard	Revoked
EP17187534A	2021-12-08	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Revoked
EP17187534A	2021-11-24	ELKINGTON AND FIFE LLP	Revoked
EP17206714A	2021-09-09	Hoffmann Eitle	Granted and Under Opposition
EP17206714A	2021-09-07	Cooke, Richard	Granted and Under Opposition
EP17206714A	2021-09-03	ELKINGTON AND FIFE LLP	Granted and Under Opposition
EP17168056A	2021-06-09	ELKINGTON AND FIFE LLP	Revoked
EP13156122A	2020-08-26	Hoffmann Eitle	Revoked
EP16152447A	2020-08-26	Hoffmann Eitle	Revoked
EP13156122A	2020-08-25	ELKINGTON AND FIFE LLP	Revoked
EP16152447A	2020-08-25	ELKINGTON AND FIFE LLP	Revoked
EP10704464A	2014-02-28	Sandoz AG	Revoked
EP10704464A	2014-02-27	Vogelsang-Wenke, Heike	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8642077	November, 2021	Terminated-Settled	Amarin Pharmaceuticals Ireland Limited	Hikma Pharmaceuticals USA Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700537	AMARIN PHARMS	Composition for preventing the occurrence of cardiovascular event in multiple risk patient	May, 2027 (4 years from now)
US9198892	AMARIN PHARMS	Composition and/or method for preventing onset and/or recurrence of cardiovascular events	Sep, 2027 (4 years from now)
US8440650	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8293728	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8415335	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8546372	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8680144	AMARIN PHARMS	Methods of treating mixed dyslipidemia	Feb, 2030 (6 years from now)
US8518929	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8524698	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8314086	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8318715	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8367652	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8399446	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8431560	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8293727	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8426399	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8377920	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US8357677	AMARIN PHARMS	Methods of treating hypertriglyceridemia	Feb, 2030 (6 years from now)
US10010517	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8445003	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8563608	AMARIN PHARMS	Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy	Apr, 2030 (7 years from now)
US11154526	AMARIN PHARMS	Methods of treating mixed dyslipidemia	Apr, 2030 (7 years from now)
US8623406	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8617593	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US10792267	AMARIN PHARMS	Methods of treating mixed dyslipidemia	Apr, 2030 (7 years from now)
US10842766	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US10881632	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US11103477	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8454994	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US11213504	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8298554	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8618166	AMARIN PHARMS	Methods of treating mixed dyslipidemia	Apr, 2030 (7 years from now)
US8642077	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8703185	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8691871	AMARIN PHARMS	Methods of treating mixed dyslipidemia	Apr, 2030 (7 years from now)
US8709475	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8501225	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US10265287	AMARIN PHARMS	Methods of reducing triglycerides and LDL-C	Apr, 2030 (7 years from now)
US8445013	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8617594	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US8551521	AMARIN PHARMS	Stable pharmaceutical composition and methods of using same	Apr, 2030 (7 years from now)
US10842768	AMARIN PHARMS	Compositions and methods for lowering triglycerides	Jun, 2030 (7 years from now)
US8710041	AMARIN PHARMS	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy	Jun, 2030 (7 years from now)
US8669245	AMARIN PHARMS	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy	Jun, 2030 (7 years from now)
US8410086	AMARIN PHARMS	Compositions and methods for lowering triglycerides	Jun, 2030 (7 years from now)
US8455472	AMARIN PHARMS	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy	Jun, 2030 (7 years from now)
US11298333	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US9603826	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9610272	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9623001	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693984	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693985	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693986	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9918954	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10278935	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10278937	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10278936	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10383840	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10555925	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10555924	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10568861	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10668042	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US10576054	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10792270	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10786478	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US10894028	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US11000499	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US11116742	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US11369582	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 13, 2022

Market Authorisation Date: 26 July, 2012

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia; Use of vascepa as an adjunct to statin therapy to reduc...

Dosage: CAPSULE;ORAL